Apellis reports Q3 EPS $1.71, consensus 94c

Reports Q3 revenue $458.578M, consensus $409.16M. “The third quarter was marked by strong execution and meaningful progress across our commercial and development portfolio. We were thrilled to receive our third regulatory approval in just four years, introducing a first-in-class C3 therapy for patients with C3G and primary IC-MPGN, many of whom previously had no available treatment options. The positive reception from the nephrology community reflects recognition of EMPAVELI’s compelling efficacy and safety profile, and strengthens our confidence in its potential to become the treatment of choice for patients,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis (APLS). “At the same time, SYFOVRE continues to lead the geographic atrophy market and deliver a steady, durable revenue stream that supports our long-term growth ambitions. Combined with our strong financial position, these achievements enable us to enter the fourth quarter and 2026 with a solid foundation and clear momentum for continued growth.”